OUR NEWS

As one of Europe’s leading spring biotech partnering events, BIO-Europe Spring is built around intensive one-to-one meetings that bring together biotech, pharma, and investors in a highly focused setting. It’s always a busy and productive few days, with packed schedules and valuable opportunities to start new conversations and strengthen existing relationships. If you’d like to meet with the rAAVen team during the event, please reach out directly or send us a request through the partnering platform.

Looking forward to attending #BIOEurope in Vienna. At rAAVen Therapeutics, we engineer next-generation AAV capsids to increase specificity, reduce immunogenicity, and improve manufacturability. If you’re exploring gene delivery beyond the usual serotypes—or want to learn more about rAAVen—let’s connect. DM me or send a meeting request via the partnering platform.

We’re at BioJapan in Yokohama!
If you’re working on AAV capsid engineering or targeted delivery, we are available for meetings to share the latest updates from rAAVen Therapeutics. Reach out anytime during the event—or afterward—to talk AAVs and gene therapy.

Excited to announce that #rAAVen will be at #ESGCT2025 in Sevilla! Our team members, Dr. Yuriy Pomeshchik and Fanny Andersson, will be attending in person. If you’re interested in exploring potential collaborations or discussing AAVs tailored to your research needs, we’d love to connect—feel free to reach out to schedule a meeting.   We’re also thrilled to share our poster presentation: Poster P0003 – Rational AAV Screening Platform Uncovers Novel Capsids for CNS and Peripheral Organs Date: October 8, 2025 Time: 14:00 – 15:30   Looking forward to engaging with fellow scientists, sharing insights, and sparking new ideas at the conference!

We’re thrilled to share that rAAVen, represented by Patrick Aldrin-Kirk, won 1st place in the Startup Pitch Challenge at #LifeSciencesBaltics2025! Huge thanks to the organizers and to the Ohio Small Business Development Center at Ohio University and Startup Lithuania for the award.

Let’s talk AAVs! rAAVen Therapeutics will be at BIO International Convention in Boston, June 16-19. Meet our COO Marcus Davidsson to explore the latest in capsid engineering for CNS and peripheral organ targeting. Reach out to connect — we’re happy to share insights, updates, and partnership opportunities. 

Just back from #ASGCT2025 — an inspiring week filled with outstanding science, fresh ideas, and the joy of reconnecting with friends and collaborators across the gene therapy community. At #rAAVenTherapeutics, we were proud to share our latest advances in AAV engineering: - Oligodendrocyte-targeting AAVs: Our rational AAV peptide platform identified candidates that efficiently and specifically target oligodendrocytes via intraventricular delivery, outperforming benchmark capsids. (In collaboration with #MyrtelleInc) - CSF-delivered AAV library targeting astrocytes in NHPs — available for partnering - IV-delivered AAV libraries targeting skeletal muscle, heart, and pancreatic islets in NHPs — available for partnering - IV-delivered AAV library targeting glomerular kidney cells in rodents — available for partnering - Hyper-efficient AAVs enabling broad brain spread at ultra-low titers via direct injection — available for partnering We’re excited about the opportunities ahead and open to discussions! 

The ASGCT Annual Meeting continues to serve as a premier platform for innovation and collaboration in the field of gene and cell therapy. This year’s event, held from May 13–17, 2025, in New Orleans, will feature over 2,100 presentations across plenary sessions, oral abstracts, and poster discussions—highlighting key advancements and novel research.   rAAVen Therapeutics is pleased to announce that our leadership team—Dr. Marcus Davidsson, Dr. Patrick Aldrin-Kirk, and Dr. Yuriy Pomeshchik—will be be there in person. If you’re interested in exploring potential collaborations or discussing novel AAVs specifically engineered for your needs, we welcome the opportunity to connect—please feel free to reach out to arrange a meeting.   We also invite you to join us at our poster presentation: Poster #1895 – Rewriting Tropism: Engineered AAV-Kingfisher Capsids Show Superior Oligodendrocyte Targeting and Spread Date: May 15, 2025 Time: 5:30 PM – 7:00 PM   We look forward to engaging with fellow scientists and exchanging ideas during the conference. 

Exciting Milestone in Gene Therapy Collaboration We are proud to announce a significant milestone in our collaboration with Myrtelle on advancing AAVs targeting oligodendrocytes. Several novel AAV capsid variants have been successfully validated through intrastriatal and intraventricular injections. This achievement is a crucial step toward validating these variants in non-human primates (NHPs) and represents meaningful progress in developing innovative gene therapies targeting oligodendrocytes. A big thank you to the teams at both organizations for their expertise and dedication in driving this work forward. We look forward to continuing this important collaboration as we explore new opportunities in gene therapy. (Image shows an intraventricular injection of an AAV-Kingfisher variant (GFP) targeting oligodendrocytes (Olig2) in corpus callosum)

We had the privilege of visiting the beautiful city of Lyon, where we had the opportunity to work with CYNBIOSE and CRCL Centre de Recherche en Cancérologie de Lyon on an AAV screening assay in non-human primates. We would like to express our sincere gratitude to the Cynbiose team, including Joachim Confais and Alexia Aufrere, and the CRCL team, comprising Cyril Dégletagne, Thibault Andrieu, Priscillia BATTISTON-MONTAGNE, Mélina Gautier and Samantha BALLESTA, for their exceptional hospitality and outstanding support. We look forward to future collaborations on AAV screenings and further advancing this important work. 

Together with fellow SmiLe Incubator alumni community member Cellevate, rAAVen Therapeutics announces the start of a shared project. Within this project rAAVen will design and produce a targeted AAV library, for testing and assessment of the Cellevate3dTM nanofiber microcarrier.

rAAVen Therapeutics announces the hiring of Yuriy Pomeshchik MD, PhD as Director of In Vitro. Before joining rAAVen, Yuriy held a position as Associate Researcher at Lund University.

rAAVen Therapeutics is pleased to share the news on our participation in this year’s  #ASGCT2024, and the symposium held by Myrtelle, Inc., where we will be presenting the latest findings on AAVs targeting oligodendrocytes.

rAAVen Therapeutics is excited to announce a new partnership with Prevail Therapeutics to develop novel adeno-associated virus (AAV) capsids for disorders of the nervous system. (link)

rAAVen Therapeutics has gone into an agreement, for a continuous partnership with Myrtelle, Inc. In the new collaboration rAAVen will validate a defined number of capsids from the previously performed oligodendrocyte screening assay.

Lena Mårtensson has been assigned to the rAAVen Therapeutics Board of Directors. Lena has an extensive background within Life Science, with multiple project and business development roles in i.e AstraZeneca and Pharmacia/Pfizer.

rAAVen Therapeutics will participate in the Viral Vector Formulation Process & Development Summit in Amsterdam 11-13 June. Our CSO, Patrick Aldrin-Kirk, will present the rAAVen platform, and what makes us the go to alternative when it comes to novel AAV capsid engineering. (link)​

rAAVen Therapeutics is pleased to announce a new joint Photochemical Lysis project with PCI Biotech. In the project, rAAVen will develop and produce AAV, as well as perform research.

rAAVen Therapeutics hires Patrick Aldrin-Kirk, PhD as its new Chief Scientific Officer. Before joining rAAVen, Patrick did his postdoc and held a position as Associate Professor at Copenhagen University, Denmark.​

rAAVen Therapeutics is excited to announce a new partnership with Myrtelle, Inc. to develop novel adeno-associated virus (AAV) capsids targeting oligodendrocytes. (link)​